Probability of 5-year EFS calculated using the Kaplan-Meier method for patients with MLBL compared with stage III non-MLBL DLBCL patients treated on Group B therapy in the FAB/LMB 96 study. The 5-year EFS for MLBL patients was 66% (95% CI, 49%-78%) and for stage III non-MLBL DLBCL patients, it was 85% (95% CI, 71%-92%; P < .001).